title: The benefits of early androgen blockade.
abstract: Altering the effects of testosterone on prostate cancer cells by blocking androgen production or action is a critical part of treating this malignancy. The appropriate timing of androgen blockade for advanced prostate cancer is controversial. Despite many phase-III studies, gaps in clinical information still remain, and some questions are still not conclusively answered. This review concentrates on high-level evidence to address common clinical situations in advanced and metastatic prostate cancer. Additionally, the side-effects of androgen blockade have become increasingly visible and relevant.
authors.affiliation: The University of Colorado at Denver and Health Sciences Center, Academic Office One Bldg, Aurora, CO 80045, USA. paul.maroni@uchsc.edu
authors.forename: Paul D
authors.initials: PD
authors.lastname: Maroni
authors.forename: E David
authors.initials: ED
authors.lastname: Crawford
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000728:Androgens / Q000378:metabolism; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003131:Combined Modality Therapy; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D020360:Neoadjuvant Therapy / Q000009:adverse effects; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D018931:Antineoplastic Agents, Hormonal